Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, November 10, 2022, after the market close.
SALT LAKE CITY, Oct. 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, November 10, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The call and webcast will be available via:
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website. About Co-Diagnostics, Inc.:
SOURCE Co-Diagnostics |
||||||
Company Codes: NASDAQ-SMALL:CODX |